title: [Long-term efficacy of naftopidil for treatment of lower urinary tract symptoms with benign prostatic hyperplasia].
abstract: Naftopidil was administered to 67 patients with benign prostatic hyperplasia (BPH) for 12 months. Changes in total/each International Prostate Symptom Score (IPSS) for irritative and obstructive symptoms, nocturia, and residual urine volume were compared before and after its administration. As a result, a significant decrease of score was found in total-IPSS, obstructive and irritative symptoms, which also showed a tendency to decrease at the end of the first month. Nocturia and residual urine volume also significantly decreased after its administration. Naftopidil is considered to be effective in the treatment of BPH, especially irritative symptoms including nocturia in treatments for BPH, because both irritative and obstructive symptoms (IPSS subjective endpoints) and residual urine volume (objective endpoint) were improved after its long-term administration.
authors.affiliation: Department of Urology, Akasaka Hospital.
authors.forename: Toshiyuki
authors.initials: T
authors.lastname: Akasaka
authors.forename: Hiroyoshi
authors.initials: H
authors.lastname: Funaki
authors.forename: Shigeru
authors.initials: S
authors.lastname: Hirano
authors.forename: Mitsuru
authors.initials: M
authors.lastname: Ohinata
authors.forename: Mikihiko
authors.initials: M
authors.lastname: Fujishima
authors.forename: Takuji
authors.initials: T
authors.lastname: Kudou
authors.forename: Akira
authors.initials: A
authors.lastname: Suzuki
authors.forename: Masahiro
authors.initials: M
authors.lastname: Iinuma
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage* / Q000494:pharmacology; D000368:Aged; D000369:Aged, 80 and over; D004334:Drug Administration Schedule; D006801:Humans; D008297:Male; D008875:Middle Aged; D009281:Naphthalenes / Q000008:administration & dosage* / Q000494:pharmacology; D010879:Piperazines / Q000008:administration & dosage* / Q000494:pharmacology; D011470:Prostatic Hyperplasia / Q000150:complications*; D011788:Quality of Life; D014555:Urination Disorders / Q000188:drug therapy* / Q000209:etiology; D014563:Urodynamics / Q000187:drug effects
chemical_list: D000317:Adrenergic alpha-Antagonists; D009281:Naphthalenes; D010879:Piperazines; C064357:naftopidil